Scientific foundations
Mechanism, reproducibility, model selection and the limitations of existing evidence.
InVentures / Health & human longevityScientific depth.
[ INVESTMENT THEMES / HUMAN LONGEVITY ]
Scientific depth.
Human relevance.
Helping biotechnology and medical founders connect rigorous science with a credible development plan, a clear clinical context and an investment case grounded in evidence.
A translational view of company building.
The health platform brings together expertise in materials science, biotechnology, clinical practice, translational medicine and commercial development. The focus is on making the path from a scientific finding to a usable intervention understandable and testable.
Development strategy
Preclinical plans, clinical context, regulatory milestones and specialist review.
Commercial readiness
IP, manufacturing assumptions, partnerships and the resources required for the next stage.
[ A MORE PRODUCTIVE NEXT CONVERSATION ]
Start with what you can show.
- Separate demonstrated findings from proposed mechanisms and forecasts.
- Define the next experiment and development decision.
- Build a milestone-based plan that connects evidence and capital.
[ FEATURED RESEARCH / WRIGHT HEALTH ]
Two research paths. One translational ambition.
Explore Wright Health’s oncology and skin and tissue programs, the scientific foundations and the evidence required for the next development milestone.
Explore Wright Health ↗Research-stage programs. Scientific rationale and conceptual imagery are not clinical evidence of efficacy.
[ THE HEALTH & HUMAN LONGEVITY TEAM ]
General Partner - Health & Human Longevity Fund
Gerardo Garza
A materials science engineer with over 20 years of experience in R&D and 5 patented technologies, Gerardo has spent his career turning deep scientific expertise into scalable ventures. He began by building and exiting a firm that helped companies commercialize their intellectual property and navigate research and development — work that gave him a front-row seat to how innovation actually moves from lab to market. From there, he founded a protein design and expression company, which became the seed of something bigger: Gene Paradox, where he built an AI platform to help teams predict outcomes in synthetic biology — four years before that kind of thinking became mainstream. Today, Gerardo focuses on what he knows best: helping founders with deep technology find their footing in the U.S. market. He works closely with Latin American biotech and medical companies, guiding them through mentorship and curating dealrooms that speak the language of serious investors. At InVentures, he brings that same lens to the medical and biotech vertical — helping founders not just tell their story, but structure it in a way that reflects the rigor, credibility, and commercial potential that top-tier investors are looking for. If you've built something real in biology or medicine, Gerardo has been exactly where you are and knows the path forward.
Book a conversation ↗
General Partner - Health & Human Longevity Fund
Neil Verity, Ph.D.
A drian "Neil" Verity, Ph.D. is a pharmaceutical executive and translational scientist with more than 30 years of experience advancing breakthrough therapeutics from discovery through regulatory approval. His expertise spans pharmacology, toxicology, clinical development, regulatory strategy, and drug commercialization across global pharmaceutical companies and emerging biotechnology ventures. As Executive Director of Pharmacology and Principal Scientist at DURECT Corporation, Dr. Verity helped lead the development of POSIMIR®, guiding the program from concept through FDA approval. Throughout his career, he has developed therapies across oncology, neuroscience, metabolic disease, pain management, and advanced drug delivery while working extensively with the FDA and international regulatory agencies. At InVentures Health, Dr. Verity provides strategic guidance on translational medicine, preclinical development, IND strategy, regulatory planning, and clinical execution. His ability to bridge scientific innovation with product development helps founders accelerate promising therapies toward clinical and commercial success.
Explore meeting calendars ↗
General Partner - Health & Human Longevity Fund
H. Joseph Yoon, MD
Dr. Hojung Joseph Yoon is a board-certified physician, healthcare entrepreneur, and scientific advisor who integrates clinical excellence, translational research, health informatics, and strategic leadership. He brings a rare multidisciplinary perspective to chronic disease as well as medical device innovation. His research experience spans Harvard University, the University of Minnesota, and Williams College, focusing on genetics and protein-based therapeutics targeting obesity. Dr. Yoon trained clinically at Columbia Presbyterian Medical Center and maintains membership in the Society for Neuroscience, with a focus on neurological reward pathways. He further specialized through a National Library of Medicine Health Informatics Fellowship. Previously, as Director of U.S. Medical Affairs for a Korean medical device startup, he spearheaded U.S. market expansion, overseeing scientific communications, marketing strategies, and the FDA approval process.
Explore meeting calendars ↗[ LET’S BUILD WHAT’S NEXT ]
Move the conversation forward.
Share where you are today, what you have demonstrated and the decision you need to make next.